info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Doxorubicin Market Analysis

ID: MRFR//5907-HCR | 85 Pages | Author: Rahul Gotadki| June 2024

The supply, demand and performance of a widely used chemotherapy drug, Doxorubicin depend on the market dynamics, which in turn are influenced by several factors that affect the pharmaceutical industry. First and foremost, the increased incidence of cancer globally has been one of the key drivers for growth in the Doxorubicin market. Consequently, as different types of cancers increase in number so does the need for efficient chemotherapy agents including doxorubicin becomes higher.

On top of this, competitive environment plays a vital role in shaping the dynamics of this market. There is a mix up between competition and collaboration due to many drug manufacturers who produce and develop Doxorubicin. This competition affects pricing strategies as well as propelling innovation among firms while aiming at distinguishing their products through improved formulation and delivery mechanisms.

Regulatory factors are also important determinants in influencing Doxorubicin market. Stringent requirements for drug approval particularly when dealing with oncology drugs make it difficult environment for players to operate within. The regulatory landscape affects time and cost relating to bringing both doxorubicin and its thereof into the market place but also ensures higher quality and safety standards that are critical in relation to cancer treatment.

Availability of raw materials and complexity involved in manufacturing contribute to overall market dynamics on supply side. Synthesis of Doxorubicin involves complex chemical processes which if interfered with can disrupt availability of drug production chain .Therefore monitoring supply chain changes by market players will help keep viable production process across all time periods.

Doxorubicin’s pricing dynamics are determined by various factors such as costs associated with production ,competition policies ,and healthcare system regulations among others . High costs associated with research, development, and manufacturing have implications on final prices charged on doxorubicin thereby making it significant to manufacturers as well as consumers alike.In addition to that there is generic doxorubicins existence leading to low-costs hence favoring patients and healthcare systems.

Furthermore, the market dynamics of Doxorubicin are affected by the global economic environment. This may differ in various regions due to economic fluctuations, exchange rates and expenditure patterns on health care which may either lead to a higher or lower accessibility and affordability of doxorubicin. This matter is particularly relevant as health systems and patients attempt to control costs while ensuring access to essential treatments.

The landscape for Doxorubicin keeps evolving because of technology advancements and ongoing research. This influences its market acceptance since innovations like liposomes aim at enhancing its efficacy while minimizing side effects. Furthermore, there are still ongoing clinical trials seeking new uses for Doxorubicin as well as new combinations with other treatments for cancer which could further expand its market coverage in future.”

Covered Aspects:

Report Attribute/Metric Details

Doxorubicin Market Overview


The Doxorubicin Market is projected to reach USD 1383.75 Million by 2030 at 6.20% CAGR during the forecast period 2022-2030. Doxorubicin is the generic drug used to treat cancer chemotherapy drugs Adriamycin and Rubex. It is an anthracycline antibiotic and belongs to the anti-cancer group of anti-cancer. The medications are antineoplastic and are made from the natural product produced by the bacterium Streptomyces peucetius var. caesius. Doctors use this for the treatment of different types of cancer. The cancers that can be treated through this are breast, stomach, ovary, bone, testicles, bladder, lung, soft tissue, osteogenic sarcoma, Wilms' tumour, Hodgkin's, and non-Hodgkin's lymphomas. Less commonly, it is also used to treat squamous cell carcinomas of the head and neck. Vagina and cervix, multiple refractory myeloma, and neuroblastoma. Doxorubicin slows down the proliferation rate of cancerous cells by intercalating between the base pairs in the DNA helix. And this can prevent DNA replication and inhibit protein synthesis. The market is facing good growth due to several reasons. One of the major reasons is the rise in cancer patients worldwide, which is the main cause of death. The lifestyle that people are adopting, which causes more cancer cells in the body, is another cause of the growth.


Segmentation


The doxorubicin market has been segmented on the basis of application, and distribution channel.


The application segment is divided into liver cancer, gastric cancer, breast cancer, bone sarcoma, prostate cancer, stomach cancer, ovarian cancer, leukemia and others.


The market, by distribution channel, has been segmented into hospital pharmacy, retail pharmacy and others.


The doxorubicin market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The doxorubicin market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Doxorubicin Market Share, by Region, 2017 (%)


Doxorubicin Market


Source: MRFR Analysis


The Americas are expected to dominate the doxorubicin market owing to the growing pool of cancer patients associated with increasing elderly population, strong presence of major manufacturers in the region, and adoption of advanced healthcare facilities coupled with increased awareness about cancer treatment in general population. In 2016, according to the National Cancer Institute in United states approximately USD 147.3 billion were spend for cancer care and around 15.5 million new cases of cancer were registered.


The European market is expected to be the second-largest doxorubicin market. The market growth in this region can be attributed to the growing prevalence of cancer along with rising healthcare expenditure is expected to drive the growth of the market. In 2016, according to European commission, the European nations invested 16.2% of its total expenditure on healthcare.


Asia-Pacific is expected to be the fastest-growing doxorubicin market during the forecast period owing to the continuously increasing investment in healthcare, increasing geriatric population in the region, and increasing opportunities for various manufacturers. According to the Economic and Social Commission for Asia and the Pacific (ESCAP), 12.4% of the total Asian population is 60 or above 60-year-old and by 2050 one third of the population will cross 60 year.


The market in the Middle East & Africa is expected to account for the smallest share of the doxorubicin market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.


Market of Doxorubicin, by Application



  • Liver cancer

  • Gastric cancer

  • Breast cancer

  • Bone sarcoma

  • Prostate cancer

  • Stomach Cancer

  • Ovarian cancer

  • Leukemia

  • others


Market of Doxorubicin, by Distribution Channel



  • Hospital pharmacy

  • Retail pharmacy

  • Others


Market of Doxorubicin, by Region



  • Americas


    • North America


      • US

      • Canada


    • South America


  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • The Middle East & Africa


    • Middle East

    • Africa



Company Profiles



  • Pfizer, Inc

  • Sun Pharmaceutical Industries Ltd.

  • Janssen Pharmaceuticals

  • Accord Healthcare

  • Novartis AG

  • Sandoz

  • Reddy’s Laboratories Ltd.

  • Teva Pharmaceuticals

  • GLENMARK PHARMACEUTICALS LTD.


Recent Development


April 2022


The research group of the University of Manitoba in Canada found that vitamin C improved markers of heart health and survival in rats given doxorubicin, mainly by reducing oxidative stress and inflammation. The new study assessed whether vitamin C could similarly help prevent doxorubicin's adverse effects on skeletal muscle.


The research found that DDX3X expression was significantly decreased in H9c2 cardiomyocytes treated with Dox. Ddx3x knockdown and RK-33 (DDX3X ATPase activity inhibitor) pretreatment exacerbated cardiomyocyte apoptosis and mitochondrial dysfunction induced by Dox treatment.


 May 2022


A team of researchers from the National University of Singapore (NUS) is best for novel magnetic therapy. This is delivered using the OncoFTX System, which serves as an effective companion therapy to chemotherapy to enhance treatment outcomes for breast cancer.Intended Audience



  • Doxorubicin manufacturing suppliers and companies

  • Healthcare providers

  • Research institutes and academic centers

  • Contract manufacturing organizations (CMOs)

  • Market research and consulting

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.